Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis
Renovion Completes Enrollment in Phase 2 CLIMB Study in Bronchiectasis
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Renovion has enrolled the first subject in a Phase II clinical trial of investigational nebulised therapy, ARINA-1, for the treatment of adult non-cystic fibrosis bronchiectasis (NCFBE) patients.
CHAPEL HILL, N.C. & MIAMI--(BUSINESS WIRE)--Renovion and COPD Foundation Joint Release – Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) (NCT05495243).
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for serious chronic inflammatory lung diseases with high unmet needs, announced today that they have received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to investigate ARINA-1 in the prevention of Bronchiolitis Obliterans Syndrome (BOS) progression in patients that have had a bilateral lung transplant. ARINA-1 is a nebulized therapy that has been shown to be safe and improve pulmonary function and quality of life in patients with a lung transplant.
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for rare, chronic, and serious lung diseases with high unmet needs, announced today that they have received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial to investigate ARINA-1 in non-cystic fibrosis bronchiectasis (NCFBE). ARINA-1 is a nebulized therapy that thins mucus and enables mucus clearance from the lungs while decreasing pathological inflammation.
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion today announced that Dr. Martin “Marty” Zamora, MD, has joined Renovion as Chief Medical Officer. Dr. Zamora will lead the Phase 3 NDA-enabling clinical program in lung transplant and provide clinical expertise relative to the non-CF bronchiectasis (NCFBRE), non-tuberculosis mycobacteria pulmonary disease (NTM), and COPD programs that are also initiating this year.
CHAPEL HILL, N.C. & MIAMI--(BUSINESS WIRE)--Renovion and the COPD Foundation have announced the creation of a new partnership to accelerate the development of a novel therapy for the treatment of excessive airway mucus and inflammation in individuals with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis (CF) bronchiectasis. Phase 2 clinical trials are planned to begin in Q1 2022.
Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced the addition of Rich Mattingly to the Board of Directors. Renovion is developing ARINA-1 which is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.